Revisión
Microangiopatía trombótica secundaria y eculizumab: una opción terapéutica razonable
Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option
Elena Romána,
, Santiago Mendizábala, Isidro Jarqueb, Javier de la Rubiac, Amparo Sempereb, Enrique Moralesd, Manuel Pragad, Ana Ávilae, José Luis Górrize
Autor para correspondencia
a Servicio de Nefrología Pediátrica, Hospital Universitario y Politécnico La Fe, Valencia, España
b Servicio de Hematología, Hospital Universitario y Politécnico La Fe, Valencia, España
c Servicio de Hematología, Hospital Universitario Dr. Peset, Valencia, España
d Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, España
e Servicio de Nefrología, Hospital Universitario Dr. Peset, Valencia, España
Leído
36627
Vecesse ha leído el artículo
6602
Total PDF
30025
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 86 | 5 | 91 |
| 2025 5 | 486 | 91 | 577 |
| 2025 4 | 457 | 46 | 503 |
| 2025 3 | 513 | 85 | 598 |
| 2025 2 | 412 | 73 | 485 |
| 2025 1 | 443 | 68 | 511 |
| 2024 12 | 390 | 48 | 438 |
| 2024 11 | 480 | 110 | 590 |
| 2024 10 | 477 | 89 | 566 |
| 2024 9 | 425 | 67 | 492 |
| 2024 8 | 365 | 88 | 453 |
| 2024 7 | 587 | 54 | 641 |
| 2024 6 | 300 | 72 | 372 |
| 2024 5 | 405 | 91 | 496 |
| 2024 4 | 524 | 70 | 594 |
| 2024 3 | 433 | 59 | 492 |
| 2024 2 | 342 | 66 | 408 |
| 2024 1 | 343 | 46 | 389 |
| 2023 12 | 327 | 58 | 385 |
| 2023 11 | 548 | 126 | 674 |
| 2023 10 | 465 | 102 | 567 |
| 2023 9 | 450 | 71 | 521 |
| 2023 8 | 295 | 81 | 376 |
| 2023 7 | 335 | 44 | 379 |
| 2023 6 | 384 | 54 | 438 |
| 2023 5 | 477 | 64 | 541 |
| 2023 4 | 366 | 65 | 431 |
| 2023 3 | 480 | 61 | 541 |
| 2023 2 | 355 | 77 | 432 |
| 2022 1 | 309 | 62 | 371 |
| 2022 12 | 325 | 52 | 377 |
| 2022 11 | 362 | 60 | 422 |
| 2022 10 | 304 | 78 | 382 |
| 2022 9 | 288 | 65 | 353 |
| 2022 8 | 254 | 81 | 335 |
| 2022 7 | 252 | 92 | 344 |
| 2022 6 | 326 | 125 | 451 |
| 2022 5 | 356 | 90 | 446 |
| 2022 4 | 455 | 92 | 547 |
| 2022 3 | 322 | 102 | 424 |
| 2022 2 | 218 | 97 | 315 |
| 2021 1 | 333 | 95 | 428 |
| 2021 12 | 322 | 89 | 411 |
| 2021 11 | 358 | 85 | 443 |
| 2021 10 | 351 | 126 | 477 |
| 2021 9 | 267 | 89 | 356 |
| 2021 8 | 325 | 80 | 405 |
| 2021 7 | 296 | 70 | 366 |
| 2021 6 | 287 | 80 | 367 |
| 2021 5 | 338 | 105 | 443 |
| 2021 4 | 570 | 176 | 746 |
| 2021 3 | 355 | 82 | 437 |
| 2021 2 | 220 | 81 | 301 |
| 2020 1 | 190 | 84 | 274 |
| 2020 12 | 171 | 50 | 221 |
| 2020 11 | 242 | 81 | 323 |
| 2020 10 | 220 | 97 | 317 |
| 2020 9 | 212 | 66 | 278 |
| 2020 8 | 195 | 66 | 261 |
| 2020 7 | 241 | 52 | 293 |
| 2020 6 | 273 | 76 | 349 |
| 2020 5 | 258 | 72 | 330 |
| 2020 4 | 313 | 80 | 393 |
| 2020 3 | 202 | 58 | 260 |
| 2020 2 | 332 | 96 | 428 |
| 2020 1 | 278 | 101 | 379 |
| 2019 12 | 222 | 63 | 285 |
| 2019 11 | 297 | 90 | 387 |
| 2019 10 | 326 | 107 | 433 |
| 2019 9 | 323 | 76 | 399 |
| 2019 8 | 221 | 81 | 302 |
| 2019 7 | 261 | 69 | 330 |
| 2019 6 | 277 | 104 | 381 |
| 2019 5 | 349 | 98 | 447 |
| 2019 4 | 434 | 113 | 547 |
| 2019 3 | 339 | 90 | 429 |
| 2019 2 | 214 | 99 | 313 |
| 2019 1 | 218 | 75 | 293 |
| 2018 12 | 427 | 89 | 516 |
| 2018 11 | 824 | 31 | 855 |
| 2018 10 | 293 | 10 | 303 |
| 2018 9 | 203 | 14 | 217 |
| 2018 8 | 188 | 28 | 216 |
| 2018 7 | 161 | 13 | 174 |
| 2018 6 | 191 | 16 | 207 |
| 2018 5 | 156 | 28 | 184 |
| 2018 4 | 162 | 36 | 198 |
| 2018 3 | 181 | 24 | 205 |
| 2018 2 | 117 | 2 | 119 |
| 2018 1 | 92 | 20 | 112 |
| 2017 12 | 100 | 18 | 118 |
| 2017 11 | 193 | 20 | 213 |
| 2017 10 | 269 | 19 | 288 |
| 2017 9 | 117 | 5 | 122 |
Mostrar todo
